Methadone and metabolites in hair of methadone-assisted pregnant women and their infants

Therapeutic Drug Monitoring

Volumn 34, Issue 3, 2012, Pages 337-344

  Himes, Sarah K ^a   Goodwin, Robert S ^a   Rock, Colleen M ^b   Jones, Hendrée E ^c,d   Johnson, Rolley E ^d,e   Wilkins, Diana G ^b   Huestis, Marilyn A ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c RTI INTERNATIONAL   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e RECKITT BENCKISER   (United Kingdom)

Author keywords

EDDP; Hair; In utero exposure; Methadone; Neonatal outcomes

Indexed keywords

2 ETHYL 5 METHYL 3,3 DIPHENYLPYRROLINE; 2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; DRUG METABOLITE; METHADONE; MORPHINE SULFATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIRTH WEIGHT; CLINICAL ARTICLE; CORRELATION ANALYSIS; DRUG EXPOSURE; DRUG HAIR LEVEL; FEMALE; HAIR ANALYSIS; HUMAN; METHADONE TREATMENT; NEWBORN; OPIATE ADDICTION; OUTCOME ASSESSMENT; PREDICTION; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; FEMALE; HAIR; HUMANS; INFANT, NEWBORN; METHADONE; NEONATAL ABSTINENCE SYNDROME; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; YOUNG ADULT;

EID: 84861230268     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182512b26     Document Type: Article

References (51)

1. Jansson LM, Svikis D, Lee J, et al. Pregnancy and addiction. A comprehensive care model. J Subst Abuse Treat. 1996;13:321-329.
2. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am. 1998;25:139-151. (Pubitemid 28141705)
3. Blinick G, Wallach RC, Jerez E, et al. Drug addiction in pregnancy and the neonate. Am J Obstet Gynecol. 1976;125:135-142.
4. Naeye RL, Blanc W, Leblanc W, et al. Fetal complications of maternal heroin addiction: abnormal growth, infections, and episodes of stress. J Pediatr. 1973;83:1055-1061.
5. Jones HE, Johnson RE, Jasinski DR, et al. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend. 2005;79:1-10. (Pubitemid 41557119)
6. Kaltenbach K, Finnegan LP. Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehav Toxicol Teratol. 1986; 8:353-355. (Pubitemid 16049639)
7. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363: 2320-2321.
8. Kandall SR. Improving Treatment for Drug-Exposed Infants. Rockville, MD: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 1993.
9. Paterson S, Cordero R, McPhillips M, et al. Interindividual dose/concentration relationship for methadone in hair. J Anal Toxicol. 2003;27:20-23. (Pubitemid 36139420)
10. Goldberger BA, Darraj AG, Caplan YH, et al. Detection of methadone, methadone metabolites, and other illicit drugs of abuse in hair of methadone-treatment subjects. J Anal Toxicol. 1998;22:526-530. (Pubitemid 28457827)
11. Girod C, Staub C. Methadone and EDDP in hair from human subjects following a maintenance program: results of a pilot study. Forensic Sci Int. 2001;117:175-184. (Pubitemid 32184553)
12. Lucas AC, Bermejo AM, Tabernero MJ, et al. Use of solid-phase microextraction (SPME) for the determination of methadone and EDDP in human hair by GC-MS. Forensic Sci Int. 2000;107:225-232. (Pubitemid 30019293)
13. Marsh A, Evans MB, Strang J. Radioimmunoassay of drugs of abuse in hair. Part 2: the determination of methadone in the hair of known drug users. J Pharm Biomed Anal. 1995;13:829-839.
14. MoellerMR, Fey P,Wennig R. Simultaneous determination of drugs of abuse (opiates, cocaine and amphetamine) in human hair by GC/MS and its application to a methadone treatment program. Foren Sci Int. 1993;63:185-206.
15. Musshoff F, Lachenmeier K, Lachenmeier DW, et al. Dose-concentration relationships of methadone and EDDP in hair of patients on a methadone-maintenance program. Foren Sci Med Pathol. 2005;1:97-103. (Pubitemid 41176660)
16. Vinner E, Vignau J, Thibault D, et al. Neonatal hair analysis contribution to establishing a gestational drug exposure profile and predicting a withdrawal syndrome. Ther Drug Monit. 2003;25:421-432. (Pubitemid 36927972)
17. Kintz P, Villain M, Cirimele V. Hair analysis for drug detection. Ther Drug Monit. 2006;28:442-446. (Pubitemid 44314934)
18. Lebeau MA, Montgomery MA, Brewer JD. The role of variations in growth rate and sample collection on interpreting results of segmental analyses of hair. Foren Sci Int. 2011;210:110-116.
19. Myers RJ, Hamilton JB. Regeneration and rate of growth of hairs in man. Ann N Y Acad Sci. 1951;53:562-568.
20. Potsch L. A discourse on human hair fibers and reflections on the conservation of drug molecules. Int J Legal Med. 1996;108:285-293. (Pubitemid 26189557)
21. Saitoh M, Uzuka M, Sakamoto M. Rate of hair growth. In: Montagna W, Dobson R, eds. Advances in the Biology of Skin: Hair Growth. New York: Pergamon Press; 1967:183-201.
22. Cone EJ. Testing human hair for drugs of abuse. I. Individual dose and time profiles of morphine and codeine in plasma, saliva, urine, and beard compared to drug-induced effects on pupils and behavior. J Anal Toxicol. 1990;14:1-7. (Pubitemid 20032280)
23. Scheidweiler KB, Cone EJ, Moolchan ET, et al. Dose-related distribution of codeine, cocaine, and metabolites into human hair following controlled oral codeine and subcutaneous cocaine administration. J Pharmacol Exp Ther. 2005;313:909-915. (Pubitemid 40604195)
24. Lynfield YL. Effect of pregnancy on the human hair cycle. J Invest Dermatol. 1960;35:323-327.
25. Fitzsimons HE, Tuten M, Vaidya V, et al. Mood disorders affect drug treatment success of drug-dependent pregnant women. J Subst Abuse Treat. 2007;32:19-25. (Pubitemid 44908840)
26. Kacinko SL, Jones HE, Johnson RE, et al. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther. 2008;84: 604-612.
27. Cirimele V, Kintz P, Lohner S, et al. Buprenorphine to norbuprenorphine ratio in human hair. J Anal Toxicol. 2000;24:448-449.
28. Wilkins DG, Nagasawa PR, Gygi SP, et al. Quantitative analysis of methadone and two major metabolites in hair by positive chemical ionization ion trap mass spectrometry. J Anal Toxicol. 1996;20:355-361. (Pubitemid 26327456)
29. Garrido MJ, Troconiz IF. Methadone: a review of its pharmacokinetic/ pharmacodynamic properties. J Pharmacol Toxicol Methods. 1999;42: 61-66. (Pubitemid 30618976)
30. Rostami-Hodjegan A, Wolff K, Hay AW, et al. Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes. Br J Clin Pharmacol. 1999;48:43-52. (Pubitemid 29296662)
31. Jarvis MA, Wu-Pong S, Kniseley JS, et al. Alterations in methadone metabolism during late pregnancy. J Addict Dis. 1999;18:51-61. (Pubitemid 30053427)
32. Jeong H. Altered drug metabolism during pregnancy: hormonal regulation of drug-metabolizing enzymes. Expert Opin Drug Metab Toxicol. 2010;6:689-699.
33. Pond SM, Kreek MJ, Tong TG, et al. Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther. 1985;233:1-6. (Pubitemid 15083518)
34. Shiran MR, Lennard MS, Iqbal MZ, et al. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol. 2009;67:29-37.
35. Nanovskaya TN, Deshmukh SV, Nekhayeva IA, et al. Methadone metabolism by human placenta. Biochem Pharmacol. 2004;68:583-591. (Pubitemid 38887440)
36. Nekhayeva IA, Nanovskaya TN, Deshmukh SV, et al. Bidirectional transfer of methadone across human placenta. Biochem Pharmacol. 2005;69:187-197. (Pubitemid 39592885)
37. Kreek MJ, Schecter A, Gutjahr CL, et al. Analyses of methadone and other drugs in maternal and neonatal body fluids: use in evaluation of symptoms in a neonate of mother maintained on methadone. Am J Drug Alcohol Abuse. 1974;1:409-419.
38. Sporkert F, Pragst F. Determination of methadone and its metabolites EDDP and EMDP in human hair by headspace solid-phase microextraction and gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl. 2000;746:255-264. (Pubitemid 30657943)
39. Wilkins DG, Valdez AS, Nagasawa PR, et al. Incorporation of drugs for the treatment of substance abuse into pigmented and nonpigmented hair. J Pharm Sci. 1998;87:435-440. (Pubitemid 28175803)
40. Kintz P. Analytical and Practical Aspects of Drug Testing in Hair. Boca Raton, FL: CRC Press Taylor and Francis Group; 2007.
41. Muallem MM, Rubeiz NG. Physiological and biological skin changes in pregnancy. Clin Dermatol. 2006;24:80-83. (Pubitemid 43243073)
42. de Castro A, Jones HE, Johnson RE, et al. Methadone, cocaine, opiates, and metabolite disposition in umbilical cord and correlations to maternal methadone dose and neonatal outcomes. Ther Drug Monit. 2011;33: 443-452.
43. Doberczak TM, Thornton JC, Bernstein J, et al. Impact of maternal drug dependency on birth weight and head circumference of offspring. Am J Dis Child. 1987;141:1163-1167. (Pubitemid 17163474)
44. Kandall SR, Albin S, Lowinson J, et al. Differential effects of maternal heroin and methadone use on birthweight. Pediatrics. 1976;58:681-685.
45. Friedler G, Cochin J. Growth retardation in offspring of female rats treated with morphine prior to conception. Science. 1972;175:654-656.
46. de Castro A, Jones HE, Johnson RE, et al. Maternal methadone dose, placental methadone concentrations, and neonatal outcomes. Clin Chem. 2011;57:449-458.
47. Blinick G, Inturrisi CE, Jerez E, et al. Amniotic fluid methadone in women maintained on methadone. Mt Sinai J Med. 1974;41:254-259.
48. Blinick G, Inturrisi CE, Jerez E, et al. Methadone assays in pregnant women and progeny. Am J Obstet Gynecol. 1975;121:617-621.
49. Gray TR, Choo RE, Concheiro M, et al. Prenatal methadone exposure, meconium biomarker concentrations and neonatal abstinence syndrome. Addiction. 2010;105:2151-2159.
50. Jansson LM, Choo R, Velez ML, et al. Methadone maintenance and breastfeeding in the neonatal period. Pediatrics. 2008;121:106-114.
51. Mack G, Thomas D, Giles W, et al. Methadone levels and neonatal withdrawal. J Paediatr Child Health. 1991;27:96-100.